Monthly Archives: December, 2023

Browse our exclusive articles!

Sam Altman Reclaims CEO Position at OpenAI in Remarkable Employee Uprising, US

Sam Altman's remarkable comeback as CEO of OpenAI after an employee uprising. The battle for control isn't over yet, but Altman's reputation and mission-driven leadership have made him a formidable force in the AI industry. (149 characters)

Did OpenAI’s Board Warn CEO Sam Altman Before Firing? A Twist Emerges

OpenAI's board denies receiving warning letter before firing CEO Sam Altman, adding new twist to the saga. The AI safety narrative is questioned.

OpenAI’s ChatGPT Celebrates One-Year Anniversary with Impressive Growth and New Features, Turkey

OpenAI's ChatGPT celebrates its one-year anniversary with impressive growth and new features, including voice conversations and image processing. The AI chatbot has gained popularity, surpassing 1 million users in just five days and drawing 1.7 billion visits in October. Users can now subscribe to ChatGPT Plus and access ChatGPT-4, which is trained on more data and produces fewer incorrect responses. OpenAI is also creating public and private datasets to deepen AI understanding. This article discusses the evolution of AI chatbots and the future possibilities they hold.

Elon Musk’s Cozy Relationships at OpenAI Board May Have Contributed to CEO Ouster

Elon Musk's connections at OpenAI may have led to the removal of CEO Sam Altman. Musk's influence on the board raises questions about his potential business motives and ethics in AI governance.

City Councilman Uses AI Chatbot to Write Landmark Legislation: A Controversial Move Ignites Debate

City councilman uses AI chatbot to draft controversial legislation without informing colleagues, sparking debate over AI's role in public policy.

Popular

Tech Evolution: From Obama’s Optimism to Harris’s Vision

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tonix Pharmaceuticals TNXP Shares Fall 14.61% After Q2 Earnings Report

Tonix Pharmaceuticals TNXP shares decline 14.61% post-Q2 earnings report. Evaluate investment strategy based on company updates and market dynamics.

The Future of Good Jobs: Why College Degrees are Essential through 2031

Discover the future of good jobs through 2031 and why college degrees are essential. Learn more about job projections and AI's influence.

Pioneering Research Uncovers Vital Biomarker for Orbital Inflammation

An in-depth study reveals HLF as a potential biomarker for orbital inflammation, offering new insights for diagnosis and treatment strategies.

Subscribe

spot_imgspot_img